MultNAT® NTM Panel
Product Overview
The EasyNAT MTC/NTM Assay, conducted on Ustar’s EasyNAT® system, effectively differentiate Mycobacterium Tuberculosis Complex (MTC) and Non-Tuberculosis Mycobaceria (NTM) simultaneously from samples.
Simple process with accurate Nucleic Acid Amplification Test (NAAT) results within 54 minutes
Point-of-care Nucleic Acid Test Methodology to be applied in various medical scenarios
Differentiated MTC/NTM results facilitate physicians to provide appropriate treatment to patients
Ongoing Challanges
From 2008 to 2015, the annual incidence of NTM lung disease increased from 3.13 (95% confidence interval [CI], 2.88–3.40) to 4.73 (95% CI, 4.43–5.05) per 100,000 person-years, and the annual prevalence increased from 6.78 (95% CI, 6.45–7.14) to 11.70 (95% CI, 11.26–12.16) per 100,000 persons
The incidence and prevalence of NTM lung disease appears to be increasing in the United States, particularly among women and older age groups
Both NTM and TB can present with similar clinical symptoms and Chest X-rays, CT scans and Acid-Fast Bacilli (AFB) Smear may show similar findings in both conditions
Clinical Value
Significantly improves preliminary screening of suspected MTC/NTM cases
Auxiliary solution of bacteria-negative tuberculosis and extra-pulmonary tuberculosis
A cost-effective and time-efficient implementation for differentiating MTC/NTM
